sample text for news, o nanoCelex platform covers target discovery to identification of lead antimicrobial antibody fragments. The lead protein targets from various pathogens are identified through extensive bioinformatics and biochemical analyses and used for screening our nanoCelex antibody fragment libraries in vitro. Screening of the library will be done for multiple rounds and by applying desired selective pressure at each round to ultimately develop the optimal binding variants with desired features, e.g. resistance against heat and proteases. The optimized sequence will be further engineered for expression in appropriate expression systems and produced at commercial scale for various applications. Our infrastructure, expertise and access to large collections of well-defined environmental or clinical samples, will make AbCelex an excellent partner for discovery, development and commercialization of new diagnostic assays and devices.
Farmers use drones and data to boost crop yields
August. 13, 2015 | Camilla Cornell Special to The Globe and Mail Drones have long been used for military purposes, but…Continue reading »
BIOENTERPRISE Building Ag-Bio Based Businesses
November 27, 2014 | Safer chicken, coming right up Each year, millions of North Americans fall ill after eating chicken,…Continue reading »
AbCelex Technologies Recognized as Best Growth Company by PwC Canada
November 21, 2014| AbCelex Technologies Inc., a privately-held Canadian biotechnology company committed to the discovery and development of innovative solutions…Continue reading »